BioSpace News Archive

Farallon Capital Management is waging a proxy battle with Exelixis over R&D spending. The hedge fund issued a letter to the company’s board of directors on Wednesday.

NLRB General Counsel Jennifer Abruzzo issued a memo to all field offices clarifying the board’s recent ruling in a case regarding severance agreements.

At the World Vaccine Congress this week, Novavax presented data suggesting that its protein nanoparticle booster generated immune responses that could protect against severe infection.

Phase IIa data showed AI Therapeutics’ ALS candidate increased expression of a target engagement biomarker and led to a 73% reduction in a toxic protein aggregate.

Phase III data for Pfizer’s respiratory syncytial virus vaccine candidate showed high levels of protection for older adults and infants.

Vistagen (NASDAQ: VTGN) today announced that the European Patent Office (EPO) has granted the Company a patent for AV-101, its oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist.

Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the Canadian Intellectual Property Office (CIPO) has issued Canadian Patent No. 2,942,358 titled, “Compositions for the Treatment of Autodigestion.”

Children who need life-changing heart transplants in Florida will be able to receive free support to help improve medication adherence, which can potentially reduce the frequency of organ rejection over the next two years, thanks to a National Institutes of Health /National Heart Lung and Blood Institute Small Business Innovation Research award for $1.67M to Scene Health, a leading video medication adherence platform.

LumiraDx Limited announced its Strategic Refocus and Cost Restructuring Program aimed at reducing its scale and operations to pre-pandemic levels and to further evolve LumiraDx into an agile organization with a clear focus on the areas with the greatest potential.

Lunaphore and abcam (NASDAQ: ABCM) today announced an agreement to co-market abcam primary antibodies specifically validated for use on Lunaphore’s COMET™ platform.